A strain of Escherichia coli that produces safflower extract, its construction method and application

By constructing an Escherichia coli strain capable of producing cherry blossom extract, introducing a synthetic pathway and reconstructing shikimic acid metabolism, and utilizing kelp extract for fermentation to produce cherry blossom extract, the problems of low extraction efficiency and environmental pollution in existing technologies have been solved, achieving efficient and sustainable cherry blossom extract production.

CN121086967BActive Publication Date: 2026-11-10SOUTH CHINA UNIV OF TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511377298.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-09-25
Publication Date
2026-11-10
Estimated Expiration
2045-09-25

AI Technical Summary

Technical Problem

Existing technologies for extracting cherry blossom extract have low efficiency and are cumbersome. The chemical synthesis process is complex and causes serious environmental pollution. The reliance on traditional carbon sources has led to an increase in the demand for food resources in the bio-manufacturing industry, necessitating the development of sustainable non-food biomass alternatives.

Method used

We constructed an Escherichia coli strain capable of producing sakurain, introduced the sakurain synthesis pathway and reconstructed the shikimic acid metabolic pathway through genetic engineering and metabolic engineering techniques, and used kelp extract as a substrate to produce sakurain through fermentation. We optimized enzyme expression and carbon source utilization by employing a combination of recombinant E. coli strains and gene knockout/overexpression strategies.

Benefits of technology

It has achieved efficient production of cherry blossom extract, with a yield of 87.47 mg/L in 24 hours in a shake flask. It effectively utilizes food industry waste, reduces production costs, and solves the problems of low extraction efficiency and environmental pollution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121086967B_ABST
    Figure CN121086967B_ABST
Patent Text Reader

Abstract

This invention discloses a *E. coli* strain capable of producing cherry blossom extract, its construction method, and its applications. This cherry blossom extract-producing *E. coli* introduces a de novo synthesis pathway for cherry blossom extract and further reconstructs the shikimic acid metabolic pathway. Using glucose as the substrate alone, shake-flask fermentation can synthesize 87.47 mg / L of cherry blossom extract, which is the highest yield reported among *E. coli* strains to date. This invention also provides a method for producing cherry blossom extract through fermentation using kelp extract as a substrate. Using kelp extract as a substrate, 57.4 mg / L of cherry blossom extract can be synthesized, thereby effectively converting food industry waste into high-value products and helping to reduce production costs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of genetic engineering and metabolic engineering technology, and specifically relates to an Escherichia coli that can produce safflower extract, its construction method and application. Background Technology

[0002] Sakuranetin is a methylated flavonoid compound with a flavanone core structure. Its molecule contains hydroxyl and methoxy substituents and exists naturally in free or glycosylated forms. Originally discovered in the bark of cherry trees, it is widely found in perilla leaves, rice, cherry trees, and many other plants. Sakuranetin is a low-molecular-weight secondary metabolite with antibacterial activity. It is an essential antitoxin in plant defense systems, rapidly synthesized in plants after induced biological stress by pathogens or environmental stress, and performs the necessary inhibitory activities. It possesses multiple activities including antioxidant, antibacterial, antiviral, and anti-allergic properties.

[0003] Currently, cherry blossom extract is mainly extracted from the bark or stems and leaves of plants such as cherry trees. The extracted products are mostly mixtures, and the downstream purification process is cumbersome and has low extraction efficiency (Archiv der Pharmazie, 1908, 246(4-5): 259-272). In addition, the chemical synthesis of cherry blossom extract mainly utilizes the regioselective deacetylation of naringenin triacetate: first, naringenin is acetylated with acetic anhydride and pyridine to obtain naringenin triacetate, then treated with imidazole in 1,4-dioxane at 40°C to obtain diacetate, then treated with diazomethane solution in a mixture of diethyl ether and dichloromethane, then methylated with iodomethane in N,N-dimethylformamide (containing potassium carbonate, under alkaline conditions), then the two acetyl groups are removed by methanol in sodium methoxide solution, then the obtained free hydroxyl groups are methylated, and finally the remaining two acetyl groups are removed to obtain cherry blossom extract (Chemical and Pharmaceutical Bulletin, 2016, 64(7): 961-965). The chemical synthesis of safflower extract is complex, requires large amounts of chemical reagents, and causes significant environmental pollution; the product cannot be directly used in food or pharmaceuticals. Compared to plant extraction and chemical synthesis, the microbial synthesis of safflower extract has simple downstream operations and mainly involves multi-step enzymatic catalysis, making it eco-friendly and a promising alternative. Therefore, the application of genetic engineering and metabolic engineering techniques to produce safflower extract via microbial synthesis is being considered. However, current microbial synthesis of flavonoids still heavily relies on traditional carbon sources. Although traditional carbon sources (including starch, glucose, and other food crop-derived raw materials) are widely used in industrial fermentation processes, the rapid expansion of the biomanufacturing industry has significantly increased the demand for these food resources. Developing sustainable non-food biomass alternatives as novel carbon sources holds promise for alleviating the conflict between food supply and industrial demand.

[0004] Against this research backdrop, third-generation biomass resources using marine algae as raw materials have attracted researchers' attention. The ocean, covering over 70% of the Earth's surface, is the largest untapped treasure trove of biomass resources on Earth. Brown algae are high in carbohydrates, accounting for approximately 55-65% of their dry weight; their composition is diverse and unique, mainly including mannitol, alginate, and laminarin, as well as small amounts of other monosaccharides (such as mannose, glucose, galactose, xylose, uronic acid, or rhamnose), making them a biomass feedstock with significant application potential. Currently, biosynthetic systems utilizing algal biomass resources as raw materials mainly focus on the production of liquid biofuels such as ethanol and butanol, and their value has not yet been fully realized. Summary of the Invention

[0005] The primary objective of this invention is to overcome the shortcomings and deficiencies of the prior art and to provide an Escherichia coli that can produce cherry blossom extract.

[0006] Another object of the present invention is to provide a method for constructing the above-mentioned Escherichia coli that can produce safflowerin.

[0007] Another object of the present invention is to provide the application of the above-mentioned Escherichia coli that can produce cherry blossom extract.

[0008] Another object of the present invention is to provide a method for producing cherry blossom extract by fermentation using kelp extract as a substrate.

[0009] The objective of this invention is achieved through the following technical solution:

[0010] A type of Escherichia coli that can produce cherry blossom extract is a single Escherichia coli or a combination of upstream recombinant Escherichia coli and downstream recombinant Escherichia coli; when it is a single Escherichia coli, it has characteristics (1) to (3) or characteristics (1) to (4); when it is a combination of upstream recombinant Escherichia coli and downstream recombinant Escherichia coli, the downstream recombinant Escherichia coli has characteristic (1), and the upstream recombinant Escherichia coli has characteristics (2) to (4);

[0011] (1) Overexpression of 4-coumaroyl-CoA ligase (At4CL), chalcone synthase (PhCHS), chalcone isomerase (MsCHI), and naringenin 7-O-methyltransferase (PfOMT3);

[0012] (2) Overexpression of tyrosine ammonia-lyase (RgTAL);

[0013] (3) Knock out tyrosine synthesis transcription regulator (tyrR), knock out phenylalanine synthase (pheA), knock out glucose transport system (ptsG), knock out tyrosine efflux pump (yddG) to block the generation of byproducts and promote the efficient generation of precursor L-tyrosine.

[0014] (4) Knockout of glyoxylate dehydrogenase (adhE) and overexpression of prebenzoate dehydrogenase (tyrA) fbr ), knockout of pyruvate kinase (pykF), overexpression of DAHP synthase (aroG) fbr Knockout of acyl-CoA synthase (ascF) and overexpression of phosphoenolpyruvate synthase (ppsA) reduce carbon source consumption in the TCA cycle to provide sufficient precursors.

[0015] The upstream recombinant Escherichia coli and the downstream recombinant Escherichia coli are preferably mixed in a cell ratio of 1:3 to 3:1; more preferably in a cell ratio of 1:3 to 2:2.

[0016] The amino acid sequence of the naringenin 7-O-methyltransferase PfOMT3, as shown in GenBank accession number MT909556 or SEQ ID NO.1, consists of 353 amino acids.

[0017] The preferred sequence of the nucleic acid encoding the naringenin 7-O-methyltransferase PfOMT3 is shown in SEQ ID NO.2.

[0018] The amino acid sequence of the 4-coumaric acid coenzyme A ligase At4CL, as shown in GenBank accession number MT134263.1 or SEQ ID NO.3, consists of 562 amino acids.

[0019] The preferred nucleotide sequence of the 4-coumaric acid coenzyme A ligase At4CL is shown in SEQ ID NO.4.

[0020] The amino acid sequence of the chalcone synthase PhCHS, as shown in GenBank accession number AAF60297.1 or SEQ ID NO.5, consists of 389 amino acids.

[0021] The preferred sequence of the nucleic acid encoding the chalcone synthase PhCHS is shown in SEQ ID NO. 6.

[0022] The amino acid sequence of the chalcone flavanone isomerase MsCHI, as shown in GenBank accession number AAB41524.1 or SEQ ID NO.7, consists of 222 amino acids.

[0023] The preferred sequence of the nucleic acid encoding the chalcone flavanone isomerase MsCHI is as shown in SEQ ID NO.8.

[0024] The amino acid sequence of the tyrosine ammonia-lyase RgTAL, as shown in GenBank accession number KF765779.1 or SEQ ID NO.9, consists of 694 amino acids.

[0025] The preferred sequence of the nucleic acid encoding the tyrosine ammonia-lyase RgTAL is shown in SEQ ID NO.10.

[0026] The method for constructing the recombinant Escherichia coli producing sakurain includes the following steps:

[0027] 1) Construct expression vector A, which contains the nucleic acid encoding 4-coumaroyl-CoA ligase (At4CL) and the nucleic acid encoding naringenin 7-O-methyltransferase (PfOMT3);

[0028] 2) Construct expression vector B, which contains the nucleic acid encoding chalcone synthase (PhCHS), the nucleic acid encoding chalcone isomerase (MsCHI), and the nucleic acid encoding tyrosine ammonia-lyase (RgTAL);

[0029] 3) Construct expression vector C, which contains the nucleic acid encoding 4-coumaroyl-CoA ligase (At4CL), the nucleic acid encoding chalcone synthase (PhCHS), the nucleic acid encoding chalcone isomerase (MsCHI), and the nucleic acid encoding naringenin 7-O-methyltransferase (PfOMT3).

[0030] 4) Construct expression vector D, which contains the nucleic acid encoding tyrosine ammonia-lyase (RgTAL);

[0031] 5) Knock out the tyrosine synthesis transcription regulator (tyrR), phenylalanine synthase (pheA), glucose transport system (ptsG), and tyrosine efflux pump (yddG) of Escherichia coli chassis bacteria to obtain Escherichia coli A;

[0032] 6) Perform the following operations on E. coli A to obtain E. coli B: knock out glyoxylate dehydrogenase (adhE) and overexpress prephenylate dehydrogenase (tyrA). fbr ), knockout of pyruvate kinase (pykF), overexpression of DAHP synthase (aroG) fbr ), knockout of acyl-CoA synthase (ascF), and overexpression of phosphoenolpyruvate synthase (ppsA);

[0033] 7) Expression vectors A and B were transformed into E. coli spores to obtain recombinant strain E. coli Sak-1;

[0034] 8) Expression vectors A and B were transformed into Escherichia coli A to obtain the recombinant strain E. coli Sak-2;

[0035] 9) Expression vectors A and B were transformed into Escherichia coli B to obtain recombinant strain E. coli Sak-3;

[0036] 10) Expression vector C was transferred into Escherichia coli basalis to obtain downstream recombinant E. coli, namely recombinant strain E. coli Sak-4; expression vector D was transferred into E. coli B to obtain upstream recombinant E. coli, namely recombinant strain E. colipCA-19.

[0037] In the expression vector A, 4-coumaroyl-CoA ligase (At4CL) and naringenin 7-O-methyltransferase (PfOMT3) are expressed independently, meaning that each enzyme's coding nucleic acid has a promoter upstream.

[0038] The preferred vector backbone of the expression vector A is pACYCDuet-1.

[0039] In the expression vector B, chalcone synthase (PhCHS), chalcone isomerase (MsCHI), and tyrosine ammonia-lyase (RgTAL) are expressed independently, meaning that a promoter is located upstream of the coding nucleic acid of each enzyme.

[0040] The vector backbone of the expression vector B is preferably pRSFDuet-1.

[0041] In the expression vector C, 4-coumaroyl-CoA ligase (At4CL), chalcone synthase (PhCHS), chalcone isomerase (MsCHI), and naringenin 7-O-methyltransferase (PfOMT3) are expressed independently, meaning that each enzyme has a promoter upstream of its coding nucleic acid.

[0042] The vector backbone of the expression vector C is preferably pRSFDuet-1.

[0043] The promoter is a strong promoter; preferably a T7 promoter, i.e., P. T7 .

[0044] The promoter of the nucleic acid encoding tyrosine ammonia-lyase (RgTAL) in the expression vector D is a strong promoter; preferably the T7 promoter, i.e., P. T7 .

[0045] The vector backbone of the expression vector D is preferably pRSFDuet-1.

[0046] The Escherichia coli basal bacteria mentioned are engineered Escherichia coli strains capable of expressing exogenous proteins; preferably, Escherichia coli BL21(DE3).

[0047] The application of the above-mentioned Escherichia coli that can produce cherry blossom extract in the preparation of cherry blossom extract.

[0048] The carbon source used in the preparation is at least one of glucose, mannose, and kelp extract.

[0049] A method for producing cherry blossom extract by fermentation using kelp extract as a substrate includes the following steps:

[0050] A. Culture the above-mentioned Escherichia coli that can produce cherry blossom extract to the logarithmic growth phase or stationary phase, induce them to fully express each enzyme, and collect the bacterial cells;

[0051] B. The bacterial cells collected in step A are inoculated into a fermentation medium containing kelp extract for fermentation to obtain cherry blossom extract.

[0052] When the Escherichia coli that produces cherry blossom extract is obtained by combining upstream recombinant Escherichia coli and downstream recombinant Escherichia coli, the upstream recombinant Escherichia coli and downstream recombinant Escherichia coli are cultured and induced separately, and then mixed in a fermentation medium for fermentation.

[0053] The upstream recombinant Escherichia coli and the downstream recombinant Escherichia coli are preferably mixed in a cell ratio of 1:3 to 3:1; more preferably, they are mixed in a cell ratio of 1:3 to 2:2.

[0054] The culture medium used in step A is preferably LB medium containing antibiotics; the antibiotics are determined by the resistance of the above-mentioned Escherichia coli that produces safflowerin.

[0055] The preferred degree of cultivation in step A is OD. 600 It ranges from 0.5 to 0.8.

[0056] The inducer used in step A is preferably IPTG.

[0057] The preferred dosage of IPTG is 1 mM in the culture system.

[0058] The induction time in step A is preferably 2 to 4 hours; more preferably 3 hours.

[0059] The fermentation medium mentioned in step B is preferably M9 medium.

[0060] The composition of the M9 culture medium is as follows: 1 g / L ammonium chloride, 3 g / L potassium dihydrogen phosphate, 6 g / L disodium hydrogen phosphate, 0.25 g / L sodium chloride, 1 mM magnesium sulfate, 0.1 mM calcium chloride, 0.1 mM ferrous sulfate, pH 7.0–8.0, and deionized water as the solvent.

[0061] The kelp extract is preferably a kelp extract with a polysaccharide concentration of 35-38%.

[0062] The content of the kelp extract in the fermentation medium containing the kelp extract is 10-40% v / v.

[0063] The kelp extract is preferably prepared by the following steps: mixing kelp powder and water, extracting under heating conditions, separating solids and liquids, and selectively concentrating to obtain the kelp extract.

[0064] The kelp powder is obtained through the following steps: the kelp is cleaned, dried, ground into powder, and sieved to obtain kelp powder.

[0065] The preferred size of the sieve is 200 mesh.

[0066] The amount of water used is preferably calculated based on a material-to-liquid ratio of 1g:20-40mL; more preferably based on a material-to-liquid ratio of 1g:30mL.

[0067] The heating temperature is preferably 70-100℃; more preferably 90℃.

[0068] The preferred extraction procedure is: stirring for 90-150 minutes followed by sonication for 90-150 minutes; or more preferably: stirring for 120 minutes followed by sonication for 120 minutes.

[0069] The preferred method for solid-liquid separation is centrifugation.

[0070] The preferred centrifugation conditions are centrifugation at 8000-12000 rpm for 10-20 min; more preferably, centrifugation at 10000 rpm for 15 min.

[0071] The concentration is preferably achieved by using a rotary evaporator at 60°C until the polysaccharide does not stick to the wall.

[0072] The preferred amount of the fermentation medium containing kelp extract is 1 / 6 to 1 / 4 of the culture medium volume during cell culture; more preferably, it is 1 / 5 of the culture medium volume during cell culture.

[0073] The fermentation conditions are preferably 25–32°C with shaking culture for 20–28 h; more preferably 29–31°C with shaking culture for 24 h.

[0074] The oscillation speed is preferably 150-250 rpm; more preferably 200-220 rpm.

[0075] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0076] The present invention has the following advantages and effects compared with the prior art:

[0077] 1. The recombinant Escherichia coli provided by this invention introduces a de novo synthesis pathway for cherry blossom extract and reconstructs the shikimic acid metabolic pathway. When glucose is used as the substrate alone, 87.47 mg / L of cherry blossom extract can be synthesized in 24 hours of shake flask fermentation, which is the highest yield reported among Escherichia coli to date. Compared with the synthesis of cherry blossom extract by yeast, the time is shorter.

[0078] 2. The present invention also provides a method for producing cherry blossom extract by fermentation using kelp extract as a substrate, which can synthesize 57.4 mg / L of cherry blossom extract, thereby effectively converting food industry waste into high-value products and helping to reduce production costs. Attached Figure Description

[0079] Figure 1 This is a specific metabolic pathway diagram of the de novo synthesis of sakurain by Escherichia coli in this invention.

[0080] Figure 2 This is an overview diagram of the metabolic engineering of shikimic acid pathways.

[0081] Figure 3 This is a graph showing the effect of multiple genes involved in the metabolic engineering of the shikimic acid pathway in Example 2 on p-coumaric acid production.

[0082] Figure 4 This is a diagram showing the results of de novo synthesis of sakurain using different proportions of glucose and mannose as carbon sources in Example 4.

[0083] Figure 5 This is a diagram showing the results of the synthesis of sakurain by inoculating different proportions of upstream and downstream strains and the recombinant strain E.coli Sak-3 in Example 5. Detailed Implementation

[0084] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments of the present invention are not limited thereto.

[0085] To optimally express genes encoding exogenous enzymes, such as PfOMT3 (derived from *Perilla frutescens*, NCBI-Gene ID: MT909556), At4CL (derived from *Arabidopsis thaliana*, NCBI-Gene ID: MT134263.1), PhCHS (derived from *Petunia spp.*, NCBI-Gene ID: AAF60297.1), MsCHI (derived from *Alternanthera philoxeroides*, NCBI-Gene ID: AAB41524.1), and RgTAL (derived from *Rhododendron simsii*, NCBI-Gene ID: KF765779.1), in *E. coli* BL21(DE3), this invention optimized the expression genes using codons preferred by *E. coli*, synthesized them, and cloned them into vectors, resulting in the plasmids PUC-PfOMT3, PUC-At4CL, PUC-PhCHS, PUC-MsCHI, and PUC-RgTAL.

[0086] The gene synthesis, primer synthesis, and sequencing involved in this invention were completed by Sangon Biotech (Shanghai) Co., Ltd.

[0087] A schematic diagram of the metabolic engineering modification of the pathway for the de novo synthesis of cherry blossom extract from E. coli using kelp extract in this invention is shown below. Figure 1 , 2 As shown, the process is divided into three stages: (1) Tyrosine ammonia-lyase (TAL), 4-coumaric acid:CoA ligase (4CL), chalcone synthase (CHS), chalcone isomerase (CHI), and naringenin 7-O-methyltransferase (NOMT) ​​were introduced to construct the biosynthetic pathway of safflower extract; (2) The transcriptional regulatory factor gene tyrR, the gene pheA encoded by the byproduct phenylalanine synthase, the gene ptsG encoded by the glucose transport system, and the gene yddG encoded by the tyrosine efflux pump were knocked out to relieve the inhibition of the precursor tyrosine synthesis pathway, reduce the generation of byproducts, and increase tyrosine production; (3) The gene adhE encoded by acetaldehyde dehydrogenase, the gene pykF encoded by pyruvate kinase, and the gene ascF encoded by acyl-CoA synthase were knocked out, and the gene aroG encoded by DAHP synthase was overexpressed. fbr The gene tyrA encodes prebenzoic acid dehydrogenase. fbr The gene ppsA, encoding phosphoenolpyruvate synthase, reduces pyruvate loss, relieves tyrosine feedback inhibition, enhances DAHP synthesis, increases PEP / pyruvate supply for tyrosine synthesis, redirects carbon flow to the shikimic acid pathway, provides sufficient precursor substances, and ultimately increases the yield of safflower extract. The strains obtained according to this modification process are shown in Table 2, and the specific steps are as described in the examples.

[0088] Table 1 Primer sequences used in this invention

[0089]

[0090]

[0091]

[0092] Example 1: Construction of a recombinant strain of Escherichia coli that synthesizes safflowerin de novo from glucose

[0093] (1) Preparation of culture medium

[0094] LB (Luria-Bertani Culture) medium (1L system): 5g yeast extract, 10g tryptone, 10g sodium chloride, add deionized water to make up to 1L, sterilize at 121℃ for 20min. Before use, add kanamycin sulfate (50μg / mL), chloramphenicol (30μg / mL), and spectinomycin hydrochloride (50μg / mL) to the medium as needed. For LB solid medium, add an additional 1.5–2% agar powder.

[0095] M9 fermentation medium (1L system): 50mL 20×M9 buffer, a certain concentration of carbon source, add deionized water to make up to 1L, then adjust the pH. Before use, filter through a 0.22μm membrane for sterilization, then add 1mL of 1M magnesium sulfate solution, 0.1mL of 1M calcium chloride solution, and 0.1mL of 1M ferrous sulfate solution (trace element solutions should be prepared fresh before use), and add appropriate antibiotics as needed; 20×M9 buffer (1L system): 20g ammonium chloride, 60g potassium dihydrogen phosphate, 120g disodium hydrogen phosphate, 5g sodium chloride, add deionized water to make up to 1L, sterilize at 121℃ for 20min. In the above steps, the carbon source is 40g / L glucose, 40g / L mannose, or 10% kelp extract.

[0096] (2) Preparation of competent cells of Escherichia coli

[0097] Escherichia coli supercompetent cells were prepared using a kit (purchased from Sangon Biotech (Shanghai) Co., Ltd.). First, single colonies of the desired competent cells were inoculated into shake tubes containing 2 mL of LB liquid medium and incubated at 37°C and 220 rpm for 12 h to activate the cells. Then, 0.5 mL (1% of the culture medium volume) of the activated bacterial culture was inoculated into 250 mL Erlenmeyer flasks containing 50 mL of LB liquid medium and incubated at 37°C and 220 rpm for 2 h until the OD of the bacterial culture reached 0.5%. 600The concentration was 0.6. Then, the bacterial culture was transferred to a sterile 50 mL centrifuge tube, incubated on ice for 10 min, and centrifuged at 5000 rpm for 5 min to collect the bacterial cells. The cells were then resuspended in 16 mL of pre-chilled Buffer A, centrifuged at 5000 rpm for 5 min to collect the cells, and then fully resuspended in 4 mL of pre-chilled Buffer B. The cells were then aliquoted and stored at -80°C.

[0098] (3) Construction methods of recombinant plasmids

[0099] The PfOMT3 gene was amplified by PCR from the PUC-PfOMT3 plasmid using primer pair A1-F / A1-R, and the vector backbone was obtained by PCR amplification from the pACYCDuet-1 (chloramphenicol resistance) plasmid using primer pair A2-F / A2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pACYCDuet-PfOMT3. Similarly, the At4CL gene was amplified by PCR from the PUC-At4CL plasmid using primer pair B1-F / B1-R, and the vector backbone was obtained by PCR amplification from the pACYCDuet-PfOMT3 plasmid using primer pair B2-F / B2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pACYCDuet-PfOMT3-At4CL. The PhCHS gene was amplified by PCR from the PUC-PhCHS plasmid using primer pair C1-F / C1-R, and the vector backbone was amplified by PCR from the pRSFDuet-1 plasmid (resisted by kanamycin) using primer pair C2-F / C2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-PhCHS. Similarly, the MsCHI gene was amplified by PCR from the PUC-MsCHI plasmid using primer pair D1-F / D1-R, and the vector backbone was amplified by PCR from the pRSFDuet-PhCHS plasmid using primer pair D2-F / D2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-PhCHS-MsCHI. The RgTAL gene was amplified by PCR from the PUC-RgTAL plasmid using primer pair E1-F / E1-R, and the vector backbone was amplified by PCR from the plasmid pRSFDuet-PhCHS-MsCHI using primer pair E2-F / E2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-PhCHS-MsCHI-RgTAL. Similarly, the RgTAL gene was amplified by PCR from the PUC-RgTAL plasmid using primer pair F1-F / F1-R, and the vector backbone was amplified by PCR from the plasmid pRSFDuet-1 using primer pair F2-F / F2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-RgTAL. The At4CL gene was amplified by PCR from the PUC-At4CL plasmid using primer pair G1-F / G1-R, and the vector backbone was amplified by PCR from the plasmid pRSFDuet-PhCHS-MsCHI using primer pair G2-F / G2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-At4CL-PhCHS-MsCHI.The PfOMT3 gene was amplified by PCR from the PUC-PfOMT3 plasmid using primer pair H1-F / H1-R, and the vector backbone was amplified from the plasmid pRSFDuet-At4CL-PhCHS-MsCHI using primer pair H2-F / H2-R. The two linearized fragments were then ligated using the Gibson assembly method to obtain the plasmid pRSFDuet-At4CL-PhCHS-MsCHI-PfOMT3.

[0100] For molecular biology experiments, the specific procedures are as follows: the enzyme used for PCR amplification is PrimeSTAR Max high-fidelity PCR enzyme. After the PCR product is identified as correct by nucleic acid gel electrophoresis, the fragment is recovered using the SanPrep column DNA gel recovery kit. The target gene fragment and vector fragment are assembled using the ready-to-use seamless cloning kit from Sangon Biotech (Shanghai) Co., Ltd. The vector backbone and fragment are mixed at a ratio of 2:1. The ligation product is transformed into strain E. coli DH5α, plated on LB plates containing the corresponding antibiotics, and after culturing for 12 hours, single clones are picked for colony PCR. Positive clone plasmids are sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing.

[0101] (4) Heat shock transformation of Escherichia coli

[0102] Thaw competent *E. coli* cells on ice. After thawing, add plasmids (20 ng for single-plasmid transformation and 50 ng each for double-plasmid transformation), and incubate for 30 min to allow them to adhere to the cell membrane. Then, heat shock at 42°C for 1 min to open the cell membrane, followed by incubation on ice for 3 min to promote cell membrane healing. Add 1 mL of LB broth and incubate at 37°C and 220 rpm for 40 min on a shaker. Next, centrifuge at 4000 rpm for 2 min, discard the supernatant, resuspend the bacterial pellet, plate it, and incubate at 37°C for 12 h. Successfully transformed strains are selected through appropriate antibiotic selection.

[0103] (5) Shake-flask fermentation experiment

[0104] First, the plasmid constructed in step (3) was simultaneously transformed into E. coli BL21(DE3) competent cells using the heat shock transformation method in step (4). The cells were cultured at 37°C for 12 hours. Positive clones were screened from LB agar plates containing the appropriate antibiotics to obtain recombinant strains. Single colonies were picked and inoculated into 50 mL Erlenmeyer flasks (containing 10 mL of sterile LB liquid medium and the appropriate antibiotics), and activated at 37°C and 220 rpm for 12 hours. Then, 2% (1 mL) of activated E. coli seed culture was inoculated into 250 mL Erlenmeyer flasks (containing 50 mL of sterile LB liquid medium and the appropriate antibiotics), and cultured at 37°C and 220 rpm for 2–3.5 hours until the logarithmic growth phase OD of E. coli was reached. 600 The concentration was set to 0.6–0.8, and IPTG inducer was added to a final concentration of 1 mM. Induction was performed at 30°C and 220 rpm for 3 hours. The resulting bacterial culture was then centrifuged at 3500 rpm and 4°C for 10 minutes to collect the bacterial cell pellet. All collected bacterial pellets were then transferred to 10 mL of M9 liquid culture medium (containing sterilized carbon sources such as kelp extract / glucose / mannose, appropriate antibiotics such as kanamycin sulfate / chloramphenicol, and trace element Mg). 2+ / Fe 2 + / Ca 2+ The mixture was resuspended (with IPTG inducer) and added to a 250 mL Erlenmeyer flask. Fermentation was then carried out at 30 °C and 220 rpm for 24 h, with periodic sampling of the fermentation broth to detect product formation. Specific operating steps: 500 mL of fermentation broth was mixed thoroughly with an equal volume of HPLC methanol for 5 min, centrifuged at 12000 rpm for 5 min, and the supernatant was filtered through a 0.22 μm filter membrane.

[0105] (6) High-performance liquid chromatography (HPLC) method for the detection of flavonoids:

[0106] Instrumentation: Shimadzu high-performance liquid chromatograph with UV detector; Column: C 18 Mobile phase: pure acetonitrile and 0.1% trifluoroacetic acid aqueous solution; 0–10 min, 10–40% acetonitrile; 10–23 min, 40–60% acetonitrile; 23–28 min, 60–10% acetonitrile; 28–32 min, 10% acetonitrile; Flow rate: 1 mL / min; Injection volume: 10 μL; Column temperature: 40℃; Wavelength: 290 nm; Run time: 32 min; Retention time of safflower extract: 25.6 min; Retention time of p-coumaric acid: 14.6 min; Retention time of naringenin chalcone: 19.0 min; Retention time of naringenin: 19.6 min.

[0107] The plasmids pACYCDuet-PfOMT3-At4CL and pRSFDuet-PhCHS-MsCHI-RgTAL were transformed into wild-type upstream recombinant E. coli L21(DE3) to obtain the recombinant strain E. coli Sak-1. When 40 g / L glucose was added as the sole carbon source for shake-flask fermentation, E. coli Sak-1 produced 1.57 mg / L of sakurain, successfully establishing the pathway for de novo synthesis of sakurain in E. coli.

[0108] Example 2: Effect of knocking out genes involved in the tricarboxylic acid cycle (TCA) on the production of safflower extract.

[0109] This invention utilizes the CRISPR-Cas9 gene editing system to modify the *E. coli* genome. The sgRNA targets a specific 20-nt DNA sequence through base complementarity, guiding the Cas9 protein to cleave the target site, forming a double-strand break. Subsequently, the cell achieves gene knockout, insertion, or modification through non-homologous end joining or homologous targeted repair mechanisms. In the experiment, a dual-plasmid system was used to express the Cas9 plasmid and the sgRNA plasmid (the Cas9 plasmid carries the Cas9 gene and kanamycin resistance, while the sgRNA plasmid carries a specific sgRNA expression cassette and spectinomycin hydrochloride resistance). Combined with different antibiotic selection and compatibility replication origins, the coexistence and synergistic effect of the two plasmids were ensured, thereby achieving stable gene editing. This invention knocks out the gene *adhE*, encoded by acetaldehyde dehydrogenase, while simultaneously knocking in the gene *tyrA*, encoded by prebenzoic acid dehydrogenase. fbr For example, this can be summarized as follows.

[0110] (1) Design and construction of pTargetF plasmid

[0111] Using the online research website https: / / chopchop.cbu.uib.no / , a 20nt sequence was designed based on the CDS sequence of the target gene in *E. coli* to be knocked out. Using pTargetF plasmid as a template, full-plasmid PCR was performed using primer pair sgRNA-adhE-F / sgRNA-adhE-R to obtain linearized pTargetF-adhE. The template was then eliminated by heating with DpnI enzyme at 37°C for 1 hour. Following the method described in step (3) of Example 1, *E. coli* DH5α competent cells were transformed, plasmids were extracted, and sequencing was performed to obtain the recombinant plasmid pTargetF-adhE, which specifically recognizes the guide RNA of the adhE gene.

[0112] (2) Amplification of Donor DNA

[0113] Using the upstream recombinant *E. coli* L21(DE3) genome as a template, primer pairs adhE-up-F / adhE-up-R and adhE-down-F / adhE-down-R were designed based on the 500bp upstream and downstream sequences of the gene to be knocked out, adhE. The upstream and downstream homologous arms adhE-up and adhE-down of the gene to be knocked out, adhE-up, were amplified from the genome by colony PCR. The gene to be knocked in, tyrA, was amplified from the genome using primer pairs tyrA-F / tyrA-R (amplification of the knock-in gene is not necessary when only a specific gene is knocked out). After verifying the correct bands by running agarose gel electrophoresis, the above fragments were recovered. Using primer pairs tyrR-up-F and tyrR-down-R as templates, fusion PCR was performed to fuse the upstream and downstream homologous arms tyrR-up and tyrR-down, along with the knock-in gene tyrA, into a single fragment adhE::tyrA-Donor. After verifying the correctness of the bands by running an agarose gel, the fragment was recovered and used as the donor template adhE::tyrA-Donor for genome editing.

[0114] (3) pTargetF electroporation and gene knockout / knockin verification

[0115] Following the method described in step (4) of Example 1, the pEcCas plasmid was heat-shock transformed into the bacterial strain to be edited. After overnight culture for 12 hours, single clones with normal growth, plumpness, and a colony diameter of approximately 2 mm were picked from a plate containing kanamycin and inoculated into a shaker tube containing 2 mL of LB liquid medium (containing 50 μg / mL kanamycin antibiotic). The tubes were then cultured overnight at 37°C and 220 rpm in a constant temperature shaking incubator for 12 hours. 1% (500 μL) of the overnight culture was transferred to a 250 mL shaker flask containing 50 mL of LB liquid medium (containing 50 μg / mL kanamycin antibiotic) and cultured at 37°C and 220 rpm in a shaking incubator for 25 minutes until the bacterial culture reached OD. 600 Approximately 0.2 is sufficient. Then add L-arabinose to a final concentration of 10 mM to induce Cas9 protein expression, and continue incubation at 37°C and 220 rpm for 1.5 h until the bacterial OD reaches 0.05. 600The value was 0.6. The induced bacterial culture was collected into a 50 mL sterile plastic centrifuge tube, incubated on ice for 15 min, and centrifuged at 4000 rpm for 5 min to collect the bacterial pellet. After discarding the supernatant, the bacterial cells were slowly resuspended by pipetting with 5 mL of pre-chilled 10% sterile glycerol and centrifuged at 4000 rpm for 5 min. After discarding the supernatant again, the bacterial cells were slowly resuspended by pipetting with 5 mL of pre-chilled 10% sterile glycerol and centrifuged at 4000 rpm for 5 min. After discarding the supernatant, the collected bacterial pellet was thoroughly resuspended in 1 mL of pre-chilled 10% sterile glycerol, and 100 μL of the bacterial culture was aliquoted into sterile EP tubes for later use. Next, 100 ng of pTargetF-adhE plasmid was added to the aliquoted competent cells, followed by 400 ng of adhE::tyrA-Donor. The mixture was thoroughly mixed, then transferred to a pre-chilled 2 mm electroporation cuvette and subjected to rapid 2.5 kV electroporation. Immediately after electroporation, 1 mL of pre-cooled antibiotic-free LB liquid medium was added, gently mixed, and transferred to a clean EP tube. The tube was then incubated at 37°C and 220 rpm for 1 hour on a shaker. After antibiotic recovery, the tube was centrifuged at 3500 rpm for 3 minutes. The supernatant was discarded, and the tube was resuspended in the remaining medium. The resuspended tube was then plated onto agarose gel containing kanamycin and spectinomycin hydrochloride and incubated at 37°C for 18 hours. After overnight incubation, single colonies were randomly selected for colony PCR verification. After verifying the correct bands by running agarose gel electrophoresis, the PCR products were sent to SCI / ICM Biotechnology (Shanghai) Co., Ltd. for sequencing.

[0116] (4) Elimination of pTargetF and pEcCas plasmids

[0117] Selected bacterial strains with correct sequencing results were inoculated into shake tubes containing 2 mL of LB liquid medium (containing 50 μg / mL kanamycin antibiotic), and rhamnose was added to a final concentration of 10 mM to eliminate the pTargetF plasmid. The tubes were then incubated at 37°C and 220 rpm for 12 h with shaking. The overnight culture was diluted 1 / 1000 with LB liquid medium, and 10 μL was spread onto a plate containing kanamycin and incubated at 37°C for 12 h. Single clones from the plates were streaked onto kanamycin and kanamycin + spectinomycin hydrochloride plates, respectively. Only the strains that grew on the kanamycin plate successfully eliminated the pTargetF plasmid.

[0118] Select the strains that successfully eliminated the pTargetF plasmid and inoculate them into shake tubes containing 2 mL of LB liquid medium. Add 5 g / L glucose to eliminate the pEcCas plasmid and incubate at 37°C and 220 rpm for 12 h. Dilute the overnight culture with LB liquid medium by 1 / 1000, and spread 10 μL onto plates containing 5 g / L glucose and 10 g / L sucrose. Incubate at 37°C for 12 h. Streak the monoclonal strains from the plates onto kanamycin-free and antibiotic-free plates, respectively. The strains that grow only on antibiotic-free plates successfully eliminated the pEcCas plasmid. Prepare competent cells from the plasmid-eliminated strains.

[0119] This invention uses E. coli BL21(DE3) as the starting strain and modifies its genome using the aforementioned CRISPR-Cas9 system: ΔtyrR (primers numbered 33-38), ΔpheA (primers numbered 39-44), ΔptsG (primers numbered 45-50), ΔgltA (primers numbered 57-62), ΔyddG (primers numbered 51-56), Δldha::pgk (primers numbered 63-70), and ΔadhE::tyrA. fbr (Primers numbered 71-78), ΔpykF::aroG fbr Primers (numbered 79-86) and ΔascF::ppsA (primers numbered 87-94) were used to obtain 19 strains, named S01-S19 (e.g., ...). Figure 3 As shown), following step (5) of Example 1, plasmid pRSFDuet-RgTAL was transformed into E. coli BL21(DE3) and these 19 strains to obtain strains E. coli pCA-0 to E. coli pCA-19. Using 40 g / L glucose as the carbon source, the results of shake-flask fermentation are as follows. Figure 3As shown in the figure, knocking out tyrR relieved the inhibition of the tyrosine synthesis pathway during the synthesis process. The shake-flask fermentation results showed that the coumaric acid production of the recombinant strain EcolipCA-1 increased (from 49.62 mg / L to 126.73 mg / L). Knocking out pheA reduces phenylalanine synthesis, knocking out ptsG reduces rapid glucose uptake, lowers carbon metabolic flux, alleviates metabolic stress, and increases precursor accumulation. Knocking out yddG, which encodes a tyrosine transporter gene, reduces tyrosine efflux. This invention reconstructs the carbon metabolic pathway by knocking out tyrR, pheA, ptsG, and yddG to obtain strain S11. According to step (5) of Example 1, plasmid pRSFDuet-RgTAL is introduced into S11 to obtain recombinant strain E. coli pCA-11. Plasmids pACYCDuet-PfOMT3-At4CL and pRSFDuet-PhCHS-MsCHI-RgTAL are introduced into S1 to obtain strain E. coli Sak-2. After shake-flask fermentation with 40 g / L glucose as the carbon source, the yield of safflower extract in E. coli Sak-2 reached 18.09 mg / L (compared to the recombinant strain E. coli). Sak-1 increased by 11.5 times, and the recombinant strain E. colipCA-11 significantly increased the production of coumaric acid (346.31 mg / L).

[0120] The coumaric acid yield of strain S15 was increased to 527.9 mg / L by introducing plasmid pRSFDuet-RgTAL and using shake-flask fermentation with 40 g / L glucose as the carbon source. The coumaric acid yield of strain S18 was increased to 829.39 mg / L by introducing plasmid pRSFDuet-RgTAL and using shake-flask fermentation with 40 g / L glucose as the carbon source. The coumaric acid yield of strain S19 was increased to 1093.72 mg / L by introducing plasmid pRSFDuet-RgTAL and using shake-flask fermentation with 40 g / L glucose as the carbon source, which is about 22 times higher than that of the original strain (49.62 mg / L). A high-yielding coumaric acid strain, E. colipCA-19, was successfully obtained.

[0121] Example 3: Escherichia coli synthesizes cherry blossom extract de novo using different ratios of glucose and mannose.

[0122] In this invention, the kelp extract containing carbon sources contains mannose and glucose. Different carbon sources lead to changes in the flux of the central metabolic pathway of *E. coli*. Glucose is rapidly metabolized via glycolysis (EMP), while mannose metabolism requires conversion to fructose-6-phosphate by mannose-6-phosphate isomerase before entering the EMP pathway. Due to the carbon repression (CRR) effect of *E. coli*, it usually preferentially utilizes glucose, and the presence of glucose may inhibit the utilization of other carbon sources. Using different ratios of glucose and mannose as carbon sources, shake-flask experiments were conducted according to step (5) of Example 1. The experimental results are as follows: Figure 4 As shown, when only glucose was added as a carbon source, the highest yield of cherry blossom extract by the recombinant E. coli Sak-2 strain was 18.09 mg / L via shake-flask fermentation, while the yield of cherry blossom extract was 5.58 mg / L when only mannose was added as a carbon source. Although the metabolic efficiency of mannose is relatively low, its extremely low cost makes it a potential material for industrial applications and will help promote the low-cost biosynthesis of cherry blossom extract.

[0123] Example 4: De novo synthesis of safflower extract from Escherichia coli using kelp extract

[0124] (1) Preparation of kelp extract

[0125] Kelp collected from the coastal area of ​​Weihai, Shandong Province, was cleaned and dried in an oven at 60℃ for at least 24 hours until it became brittle. The dried kelp was then pulverized into powder using a pulverizer, passed through a 200-mesh sieve, and stored in sealed bags at 20℃ for later use. 1g of the kelp powder was then mixed with 300mL of deionized water and stirred at 90℃ for 2 hours. The mixture was then sonicated at 40kHz for 2 hours at room temperature, centrifuged at 10000rpm for 15 minutes, and the precipitate was discarded. The kelp extract was concentrated using a rotary evaporator at 60℃ until the polysaccharides no longer stuck to the walls. The resulting kelp extract was sterilized at 121℃ for 20 minutes and stored at 4℃ for later use. The polysaccharide content in the kelp extract was determined to be 36.88% using the phenol-sulfuric acid method.

[0126] (2) High-performance liquid chromatography (HPLC) method for the detection of glucose and mannose:

[0127] After centrifuging the fermentation sample at 14000 rpm for 5 min, 0.2 mL of the supernatant was added to 0.8 mL of 0.1 M dilute sulfuric acid, thoroughly vortexed, and then filtered through a 0.22 μm aqueous membrane. Measurement conditions: Instrument: Shimadzu high-performance liquid chromatograph with differential detector; Column: Bio-Rad organic acid analytical column; Mobile phase: 1 mM sulfuric acid aqueous solution; Flow rate: 0.6 mL / min; Injection volume: 10 μL; Column temperature: 40℃; Wavelength: 290 nm; Run time: 30 min; Retention time of glucose: 8.98 min; Retention time of mannose: 10.48 min. The results showed that the kelp extract contained 2.832 g / L mannose and 0.349 g / L glucose, with a mannose:glucose ratio of 8.11:1.

[0128] (3) By adding 10% by volume of kelp extract as the sole carbon source, after shake-flask fermentation with E. coli Sak-2 recombinant strain, a yield of 2.50 mg / L of cherry blossom extract was detected in the fermentation broth. A recombinant strain capable of producing cherry blossom extract by fermentation with kelp extract was successfully constructed, realizing the high-value conversion of inexpensive marine biomass and providing a new way for the efficient utilization of marine biomass resources.

[0129] Example 5: Effect of different ratios of upstream and downstream strains on the synthesis of safflower extract

[0130] Following step (5) of Example 1, plasmids pACYCDuet-PfOMT3-At4CL and pRSFDuet-PhCHS-MsCHI-RgTAL were introduced into strain S19 to obtain recombinant strain E. coli Sak-3, and plasmid pRSFDuet-At4CL-PhCHS-MsCHI-PfOMT3 was introduced into strain S19 to obtain recombinant strain E. coli Sak-4. First, the upstream recombinant strain E. colipCA-19 and the downstream recombinant strain E. coli Sak-4 were activated and then amplified to OD. 600 The initial concentration was 0.8, followed by induction for 3 hours. Bacterial cultures were collected at different ratios of 1:3, 2:2, and 3:1. All collected bacterial precipitates were resuspended in 10 mL of M9 liquid medium containing 40 g / L glucose, and then transferred to 250 mL Erlenmeyer flasks. Fermentation was carried out at 30℃ and 220 rpm for 24 hours, and the fermentation broth was analyzed. The control group consisted of only E. coli Sak-3 inoculated with M9 fermentation medium containing 40 g / L glucose for 24 hours, and the fermentation broth was analyzed. Results are as follows: Figure 5As shown, the co-culture fermentation mode is superior to the single-strain dual-plasmid fermentation (recombinant strain E. coli Sak-3, with a cherry blossom extract yield of 31.36 mg / L) described above, with the highest cherry blossom extract yield of 87.47 mg / L. This indicates that allocating the cherry blossom extract synthesis pathway to the upstream recombinant strain E. colipCA-19 and the downstream recombinant strain E. coli Sak-4 can avoid excessive metabolic burden on a single host and excessive competition for intracellular resources (such as ATP and NADPH). In this invention, the upstream strain E. coli pCA-19 focuses on synthesizing the precursor p-coumaric acid, while the downstream strain E. coli Sak-4 efficiently converts p-coumaric acid into cherry blossom extract. Furthermore, different inoculation ratios significantly affected the accumulation of paracoumaric acid and the yield of sakurain. When the inoculation ratio of upstream strain E. colipCA-19 to downstream strain E. coli Sak-4 was 1:3, the accumulation of paracoumaric acid was approximately 72.72 mg / L, and the yield of sakurain was 87.47 mg / L, which is the highest level of sakurain production reported by E. coli to date. Extending the fermentation time to 48h, 72h, 96h, and 120h, the yield of sakurain no longer increased, indicating that compared with commonly used yeast hosts in existing technologies (generally with a fermentation cycle of 72–120h), the host E. coli selected in this invention has a fermentation speed advantage, with a fermentation cycle of only 1 day. Correspondingly, when the inoculation ratio was 3:1, the upstream strain E. colipCA-19 had a stronger ability to synthesize paracoumaric acid, which may lead to a large accumulation of paracoumaric acid, resulting in a relatively low yield of sakurain (31.94 mg / L).

[0131] When 40% kelp extract by volume was added as the sole carbon source (containing 35.6 g / L mannose and 4.4 g / L glucose at the start of fermentation), the yield of safflower extract was 57.4 mg / L when the upstream strain E. colipCA-19 and the downstream strain E. coli Sak-4 were inoculated at a ratio of 1:3.

[0132] Table 2 Recombinant strains used in this invention

[0133]

[0134]

[0135] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. An Escherichia coli composition capable of producing sakurain, characterized in that: The aforementioned Escherichia coli combination capable of producing cherry blossom extract is obtained by combining upstream recombinant Escherichia coli and downstream recombinant Escherichia coli; The downstream recombinant E. coli overexpression of 4-coumarate coenzyme A ligase At4CL Chalcone synthase PhCHS Chalcone isomerase MsCHI naringenin 7-O-methyltransferase PfOMT3 ; The upstream recombinant E. coli overexpressing tyrosine ammonia-lyase RgTAL Knockout of tyrosine synthesis transcription regulators tyrR Knockout of phenylalanine synthase pheA Knock out glucose transport system ptsG Knock out tyrosine efflux pump yddG Knockout of glyoxylate dehydrogenase adhE Overexpression of prebenzoic acid dehydrogenase tyrA fbr Knockout of pyruvate kinase pykF Overexpression of DAHP synthase aroG fbr Knockout of acyl-CoA synthase ascF Overexpression of phosphoenolpyruvate synthase ppsA ; The naringenin 7-O-methyltransferase PfOMT3 The amino acid sequence is shown in SEQ ID NO.1; The 4-coumaric acid coenzyme A ligase At4CL The amino acid sequence is shown in SEQ ID NO.3; The chalcone synthase PhCHS The amino acid sequence is shown in SEQ ID NO.5; The chalcone isomerase MsCHI The amino acid sequence is shown in SEQ ID NO.7; The tyrosine ammonia-lyase RgTAL The amino acid sequence is shown in SEQ ID NO.9; The naringenin 7-O-methyltransferase PfOMT3 The sequence encoding the nucleic acid is shown in SEQ ID NO.2; The 4-coumaric acid coenzyme A ligase At4CL The sequence encoding the nucleic acid is shown in SEQ ID NO.4; The chalcone synthase PhCHS The sequence encoding the nucleic acid is shown in SEQ ID NO.6; The chalcone isomerase MsCHI The sequence encoding the nucleic acid is shown in SEQ ID NO. 8; The tyrosine ammonia-lyase RgTAL The sequence encoding the nucleic acid is shown in SEQ ID NO.

10.

2. The method for constructing the Escherichia coli composition capable of producing safflowerin as described in claim 1, characterized in that... Includes the following steps: 1) Construct expression vector C, which contains 4-coumarate-coenzyme A ligase. At4CL The encoded nucleic acid, chalcone synthase PhCHS Encoding nucleic acid, chalcone isomerase MsCHI The encoded nucleic acid, naringenin 7-O-methyltransferase PfOMT3 The encoded nucleic acid; 2) Construct expression vector D, which contains tyrosine ammonia-lyase. RgTAL The encoded nucleic acid; 3) Knockout of tyrosine synthesis transcription regulators in E. coli basal cells tyrR phenylalanine synthase pheA glucose transport system ptsG and tyrosine efflux pump yddG Escherichia coli A was obtained; 4) Perform the following operation on E. coli A to obtain E. coli B: Knock out glyoxylate dehydrogenase adhE Overexpression of prebenzoic acid dehydrogenase tyrA fbr Knockout of pyruvate kinase pykF Overexpression of DAHP synthase aroG fbr Knockout of acyl-CoA synthase ascF Overexpression of phosphoenolpyruvate synthase ppsA ; 5) Expression vector C was transformed into Escherichia coli basalis to obtain downstream recombinant Escherichia coli, i.e., the recombinant strain. E. coli Sak-4; Expression vector D was transformed into Escherichia coli B to obtain upstream recombinant E. coli, i.e., the recombinant strain. E. coli p CA-19.

3. The method for constructing the Escherichia coli composition capable of producing safflowerin according to claim 2, characterized in that: The expression vector C contains 4-coumaric acid coenzyme A ligase. At4CL Chalcone synthase PhCHS Chalcone isomerase MsCHI naringenin 7-O-methyltransferase PfOMT3 For independent expression.

4. The method for constructing the Escherichia coli composition capable of producing safflowerin according to claim 3, characterized in that: The vector backbone of the expression vector C is pRSFDuet-1; The vector backbone of the expression vector D is pRSFDuet-1.

5. The application of the Escherichia coli combination capable of producing cherry blossom extract as described in claim 1 in the preparation of cherry blossom extract.

6. The application according to claim 5, characterized in that: The carbon source used in the preparation is at least one of glucose, mannose, and kelp extract.

7. A method for producing cherry blossom extract by fermentation using kelp extract as a substrate, characterized in that... Includes the following steps: A. Culture the Escherichia coli combination that produces cherry blossom extract as described in claim 1 to the logarithmic growth phase or the stationary phase, induce it to fully express each enzyme, and collect the bacterial cells; B. The bacterial cells collected in step A are inoculated into a fermentation medium containing kelp extract for fermentation to obtain cherry blossom extract.

8. The method for producing cherry blossom extract by fermentation using kelp extract as a substrate according to claim 7, characterized in that: When the Escherichia coli combination that produces cherry blossom extract is obtained by combining downstream recombinant Escherichia coli and upstream recombinant Escherichia coli, the downstream recombinant Escherichia coli and upstream recombinant Escherichia coli are cultured and induced separately, and then mixed in a fermentation medium for fermentation. The upstream recombinant Escherichia coli and the downstream recombinant Escherichia coli are mixed in a cell ratio of 1:3 to 3:1.

Citation Information

Patent Citations

  • Genetic engineering strain taking tyrosine as substrate to synthesize naringenin and construction method thereof

    CN103484420A

  • Genetically engineered bacterium for synthesizing 4-coumaric acid and derivatives thereof as well as construction method and application of genetically engineered bacterium

    CN117737107A